BioStock: SynAct Pharma secures key US patent

SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical development for rheumatoid arthritis.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/03/synact-pharma-secures-key-us-patent/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se